CS Paper Radar

R-GEAN: Regimen-Guided Edit Action Network for Within-Admission Medication Change Prediction

Regan Mahat, Mansu Kim

cs.AI cs.IRcs.LG ·submitted 2026-09-19 11:23 UTC · v1
benchmark

Abstract

The medications prescribed to a patient often change during a hospital admission as clinicians start, stop, or continue therapies. We study whether models can predict which medication classes are added or removed between 24 hours after admission and discharge. Metrics that compare the complete discharge regimen can reward models for copying medications that remain unchanged, even when they identify no actual changes. We therefore introduce a leakage-controlled benchmark that predicts net ATC3 additions and removals using only prior completed admissions and information available within the first 24 hours of the current admission. Addition candidates are classes not active at 24 hours, whereas removal candidates are classes active at that time. We also introduce R-GEAN, an asymmetric candidate-scoring network with independent addition and removal predictors. Across 240,480 admissions from 82,286 patients, R-GEAN achieves the highest predefined summary of addition, removal, changed-regimen, and action-pattern performance, termed the edit composite (0.464), compared with 0.435 for the strongest primary comparator. Reimplemented RETAIN, GAMENet, and MICRON baselines obtain 0.428, 0.420, and 0.288, respectively. R-GEAN's advantage is concentrated in correctly identifying medication classes no longer active at discharge, while rare additions and admissions with multiple medication changes remain difficult. Rankings based on micro-F1 over the reconstructed discharge regimen and the edit composite correlate weakly across the evaluated models (Spearman r = 0.20). The continuation baseline achieves the highest complete-regimen score despite predicting no additions or removals. These results show that complete-regimen and edit-level evaluation measure different aspects of medication prediction. The benchmark evaluates observed prescribing changes, not treatment appropriateness

Closest papers

Nearest neighbours by meaning across the whole index.

Sign-Constrained Intervention Effects for Domain-Generalizable ICU World Models

cs.CE ·2026-10-08 ·Zhen Xu, Nicholas Konz, Zhen Tan, Zachary Plotkin, Tianlong Chen
similarity 0.61
Abstract · 24 pages, 6 figures, 15 tables

Predicting how a patient's vital signs respond to an intervention is a central question in intensive care. World models can do so by learning dynamics as a function of prior actions. However, such models tend to be brittle outside of training data. Clinicians choose drug dosages based on the patient's state, so the association a model learns between dose and outcome runs opposite to the drug's effect, generalizing poorly to out-of-distribution (OOD) dosing practices. Yet, pharmacological information provides the directional effects of different drugs, which are invariant to OOD shifts. To resolve the OOD sensitivity of current ICU world models, we introduce PHYSIO WORLD, which isolates an intervention's effect by evaluating a forward pass twice: once under recorded doses, and once with those doses set to zero. The difference is projected onto pharmacologically admissible effect directions stated by 70 rules over 28 drugs, leaving the magnitude to be learned from data. Across five distribution-shift parameters over cohorts from three intensive-care databases, and against forecasters, counterfactual models, and invariance objectives, PHYSIO WORLD attains the lowest OOD RMSE in every setting, improving on the strongest external baseline by 8-12%, while matching the in-distribution error of its backbone. Reversing the pharmacological directions degrades accuracy below the backbone, and data-mined directions recover almost no gain, indicating the improvement derives from the content of the pharmacological knowledge. The construction may extend to other settings where the sign of an effect is known in advance and its magnitude is confounded by treatment assignment.

0.17

Clinical Evidence-Guided Residual Learning for Medication Recommendation with Dynamic DDI Regularization

cs.LG cs.IR ·2026-11-07 ·Zesheng Li, Chengchang Pan, Honggang Qi
code/data similarity 0.61
Abstract · 13 pages, 6 figures, 8 tables. Supplementary PDF and detailed result tables are included as ancillary files. Code: https://github.com/LIZESH…

Medication recommendation must combine patient-specific treatment evidence with the interaction structure of a prescription. The central challenge is to determine which evidence supports each medication and how strongly to regularize interactions while preserving predictive quality. We propose EviDrug, a clinical evidence-guided residual learning framework. Its clinical-memory backbone integrates a self-trained visit-aware encoder, training-case memory and one medication-set interaction block to establish a patient-specific prescription. A gated refinement head combines the backbone states with clinical associations and history-conditioned medication identities through bounded logit corrections. Drug-drug interaction (DDI) feedback adapts regularization strength using training-query predictions. Across MIMIC-IV, NWICU and SICdb, EviDrug leads twelve published-method baselines in AP, F1 and Jaccard, improving AP by 2.26, 2.06 and 1.71 percentage points over the strongest comparator. These gains come at lower parameter and runtime costs than MetaDrug. Matched controls demonstrate DDI reductions with stable predictive quality. Code is available at https://github.com/LIZESHENG13/EviDrug.

0.28

MedJev: Evaluating Zero-Shot System-One Decision Making in Medicine

cs.CL cs.AIcs.LG ·2026-10-26 ·Simon A. Lee, Jiahang Sha, Moonseong Jeong, Yunbei Pan, Jeffrey N. Chiang
similarity 0.60
Abstract

System One decision models such as Jev answer structured questions in a single forward pass without generating text, offering fast and computationally efficient clinical decision support. We evaluate MedJev, an open System One model that runs locally on a laptop, across ten medical benchmarks spanning medical knowledge, diagnosis, and patient level prediction using MIMIC IV and MIMIC IV ED. We compare MedJev against zero shot LLM baselines, published GPT results, and supervised models. MedJev achieves accuracies of 72.5 percent on MedQA, 75.4 percent on USMLE, and 80.1 percent on NEJM, approaching published GPT 4 performance while maintaining well calibrated confidence estimates (ECE 0.028 to 0.063). On patient level tasks, MedJev achieves an AUROC of 0.926 for In Hospital Mortality, exceeding XGBoost (0.902), but underperforms supervised models on operational outcomes such as ED Triage Admission (0.745 vs. 0.809). Patient level predictions also exhibit substantial miscalibration (In Hospital Mortality ECE 0.286). We introduce a lightweight, two parameter recalibration method that adapts predictions to local patient populations using 50 to 200 labeled examples, reducing ECE to 0.007. Our findings establish open System One models as a promising zero shot baseline for medical AI, combining competitive predictive performance with low computational cost and efficient local calibration. We release our code and evaluation harness to support future research.

0.24

ColdDDI: Evaluating Knowledge Utilization in Cold-Start Drug-Drug Interaction Prediction

cs.LG cs.CL ·2026-10-04 ·Jiheng Liang, Chen Zhao, Di Wu, Chenyang Bu, Yunpeng Hong +2 more
publishedbenchmarkcode/data similarity 0.59
Abstract · Accepted at NeurIPS 2026 (poster). Code: https://github.com/0217ljh/ColdDDI-NeurIPS2026

Cold-start drug-drug interaction (DDI) prediction tests whether models can identify clinically significant interactions for drugs without training-time interaction history. Existing benchmarks mostly report aggregate edge-prediction scores, leaving a key evaluation question unanswered: when models receive molecular, textual, or knowledge-graph (KG) evidence, do they actually use the evidence that pharmacologically supports the interaction? We introduce ColdDDI, a reconstructible diagnostic benchmark built from DrugBank 5.1.13, with 1,900 approved small-molecule drugs and 565,731 positive DDI pairs. ColdDDI evaluates pairs with zero, one, or two unseen drugs. It also annotates each interaction by whether it changes drug exposure or drug effect, and by whether the biomedical knowledge graph contains shared enzymes, transporters, or targets that can plausibly mediate the interaction. These annotations separate evidence availability from predictive dependence. We evaluate eight conventional DDI methods and 13 LLMs; for open-weight LLMs, we test five prompt patterns and use masking, drug replacement, and channel-sensitivity metrics to probe knowledge utilization. ColdDDI exposes that, in the hardest split where both drugs are unseen, the main performance divide is mediator availability. A fine-tuned 1B LLM recovers 89-93% of interactions with a shared enzyme, transporter, or target, but only 40-62% without such a mediator. More importantly, KG-provided evidence is not always used; several KG-augmented baselines change little when the shared mediator is masked or disrupted, whereas fine-tuned LLMs respond strongly to this intervention. Thus, ColdDDI evaluates knowledge utilization rather than knowledge access alone, showing where cold-start DDI models rely on mechanistic evidence and where they fail despite receiving it. Code is available at https://github.com/0217ljh/ColdDDI-NeurIPS2026.

0.39

LeakBench: Auditing Reward Hacking through Prediction-Time Leakage in Clinical Modeling Agents

cs.CR cs.LG ·2026-10-19 ·Xiaoyuan Bao, Jingsi Jiang, Jiao Shan, Yulong Cao, Haoyu Wang +2 more
benchmark similarity 0.59
Abstract · 28 pages, 4 figures. LeakBench implementation code is not included in this arXiv version. Public companion software archives provide non-ide…

Autonomous clinical-modeling agents can optimize predictive performance while violating conditions that make a model usable. We introduce LeakBench, an executable, guideline-derived audit suite that tests agent decisions for prediction-time leakage, calibration, site-level evaluation, support awareness, and decision-curve net benefit. LeakBench combines a synthetic task with known failure structure and two real-data settings: MIMIC-IV (430k admissions) and governed multi-hospital inpatient record front-page (MHFP) data. Our primary analysis uses reward hacking descriptively, without attributing intent: an agent selects prediction-time-invalid inputs because they improve its validation reward. A deterministic optimizer and every evaluated unconstrained local-model configuration select a fatal leaking feature. In fully logged September 2026 A/B runs, DeepSeek Flash and GPT-6-astra each leak in 10/10 unconstrained runs and 0/10 runs with an explicit admission-time constraint. This contrast is version-sensitive: a blinded Claude/Fable-5.1 chat run does not leak in either condition, while explicit-constraint violations appear only in a historical August 2026 slice lacking raw trajectories. Replacing AUROC with AUPRC does not remove leakage selection. Renaming or disguising the leaking inputs changes neither selection nor provenance-based detection; a name-based filter fails. A deterministic provenance verifier-in-loop removes the leak, making the LLM repair loop defense-in-depth. Specific verifier feedback clears fatal leakage in a hosted agent, and a three-seed ablation finds principle-only feedback clears decision-level defects, though these mitigation results are limited. LeakBench treats trustworthy clinical prediction as a property of an agent's modeling process, not merely its score; it is an audit testbed with known-failure controls, not yet an expert-validated benchmark.

0.30

Disease-level drug approval forecasting from trial-agnostic public data

cs.LG q-bio.QM ·2026-09-29 ·Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos
similarity 0.58
Abstract

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through early program advancement and disease prioritization. Yet existing approaches predict outcomes at a single level or stage or do not distinguish between disease outcomes for the same drug. We ask (1) whether FDA approval can be forecast for a drug-disease pair using only pre-clinical trial information, and (2) whether these forecasts can help prioritize diseases for the same drug. We built a cohort of 14,134 drug-disease pairs by reconstructing programs from ClinicalTrials.gov, extracting disease-level approvals from FDA label documentation, and enriching each pair with molecular, disease, ADMET, target, and pathway features. We divided the cohort into pre- and post-2019 programs and trained a classifier on pre-2019 data to predict FDA approval. On the post-2019 cohort (2,637 programs), the model would have prioritized a program that ultimately gained approval over one that did not approximately three out of four times. For drugs tested across multiple diseases, selecting the model's highest-ranked disease would have identified an ultimately approved disease 61.3% of the time, compared with 40.7% under random selection. These results show that public pre-trial information contains signal for forecasting FDA approval at the drug-disease level and can help prioritize diseases for the same drug. We provide a public web tool for SMILES- and ICD-10-based drug-disease approval forecasting.

0.14

From Scores to Safe Sets: Exact Safety--Constrained Decoding for Medication Recommendation

cs.AI ·2026-10-21 ·Animesh Agarwal, Meysam Ghaffari, Nina Fatehi, Anushka Swarup, Carlos Morato
similarity 0.58
Abstract

Recent generative medication recommendation systems ultimately produce sets of drugs, but drug--drug interaction (DDI) constraints depend on the set as a whole. A natural post-hoc approach is to first predict medications and then locally repair interacting pairs by removing one drug at a time. We ask whether this local repair step itself introduces avoidable error. Using fixed medication scores from FLAME's frozen classifier on MIMIC-III, we compare increasingly strong local repair strategies with an exact global decoder while holding the scores, output size, and DDI constraint fixed. The global decoder jointly selects the highest-scoring feasible medication set using mixed-integer linear programming. Across validation and test splits, global decoding consistently achieves higher Jaccard similarity than greedy repair, degree-aware repair, and degree-aware repair strengthened with exhaustive 1-swap local search. Its advantage is small under loose DDI constraints and becomes larger as the constraint tightens; on the test split it reaches +0.0064 Jaccard over the strongest local baseline at the strict DDI operating point. The finding also holds across a fine accuracy--DDI sweep at matched realized DDI exposure and under three score representations. At the strict setting, global decoding retains more true-positive medications while removing more false positives. These results show that medication recommendation is not only a representation-learning problem: even with a frozen clinical model, how its scores are converted into a constrained medication set can materially affect the final prediction.

0.23

PerturbRx: Learning Treatment-Conditioned Latent Transitions for Patient Drug Response Prediction

cs.LG q-bio.QM ·2026-08-21 ·Yoshitaka Inoue, Minoh Jeong, Alfred Hero, Rui Kuang, Augustin Luna
similarity 0.57
Abstract

Scarce data and tumor heterogeneity limit patient-level cancer treatment-response prediction. Existing approaches predict response from pretreatment molecular profiles and drug representations, without explicitly modeling the molecular changes expected under treatment. We propose PerturbRx, a treatment-conditioned representation learning framework that learns intervention-induced latent transitions and uses them as patient-drug response features. PerturbRx trains a drug- and dose-conditioned transition predictor from context-matched but cell-unpaired control and treated single-cell populations, then freezes and transfers the predictor to pretreatment patient profiles without requiring post-treatment measurements. The transition is combined with patient and drug representations to predict response. Across TCGA and patient-derived xenograft benchmarks, PerturbRx achieves the strongest aggregate predictive performance among the evaluated methods. These results support perturbation-pretrained latent transitions as useful representations for patient-level drug-response prediction.

0.25